Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
IMUX Immunic Inc
- Stocks
- Healthcare
- NASDAQ: IMUX
Price (delayed)
$0.7272
Market cap
$69.68M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$55.58M
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's
Highlights
The company's debt has shrunk by 52% YoY and by 20% QoQ
The EPS has increased by 48% YoY and by 5% from the previous quarter
IMUX's equity has dropped by 129% since the previous quarter and by 106% year-on-year
The quick ratio has plunged by 88% YoY and by 65% from the previous quarter
Key stats
What are the main financial stats of IMUX
Market
Valuations
Earnings
Shares outstanding
95.82M
Market cap
$69.68M
Enterprise value
$55.58M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
Gross profit
$0
Operating income
-$101M
Net income
-$96.4M
EBIT
-$96.4M
EBITDA
-$96.19M
Free cash flow
-$82.85M
Per share
Balance sheet
Liquidity
EPS
-$0.95
EPS diluted
-$0.95
Free cash flow per share
-$0.82
Book value per share
-$0.06
Revenue per share
$0
TBVPS
$0.2
Total assets
$20.52M
Total liabilities
$25.8M
Debt
$210,000
Equity
-$5.29M
Working capital
-$6.62M
Debt to equity
-0.04
Current ratio
0.74
Quick ratio
0.56
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-181.3%
Return on equity
-326.9%
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IMUX stock price
How has the Immunic stock price performed over time
Intraday
1.99%
1 week
2.36%
1 month
-0.44%
1 year
-36.77%
YTD
-27.28%
QTD
4.26%
Financial performance
How have Immunic's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$101M
Net income
-$96.4M
Gross margin
N/A
Net margin
N/A
IMUX's operating income is down by 5% year-on-year and by 3% since the previous quarter
Immunic's net income has increased by 4.1% QoQ
Price vs fundamentals
How does IMUX's price correlate with its fundamentals
Growth
What is Immunic's growth rate over time
Valuation
What is Immunic stock price valuation
P/E
N/A
P/B
N/A
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has increased by 48% YoY and by 5% from the previous quarter
IMUX's equity has dropped by 129% since the previous quarter and by 106% year-on-year
Efficiency
How efficient is Immunic business performance
The company's return on equity has shrunk by 92% YoY and by 68% QoQ
The company's return on assets fell by 45% YoY and by 34% QoQ
Dividends
What is IMUX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IMUX.
Financial health
How did Immunic financials performed over time
The total assets is 20% smaller than the total liabilities
The quick ratio has plunged by 88% YoY and by 65% from the previous quarter
IMUX's current ratio has dropped by 85% year-on-year and by 58% since the previous quarter
The company's debt is 104% higher than its equity
IMUX's equity has dropped by 129% since the previous quarter and by 106% year-on-year
The company's debt has shrunk by 52% YoY and by 20% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.